Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada.
Urology. 2010 Oct;76(4):883-8. doi: 10.1016/j.urology.2009.08.028.
To complement existing data with population-based cancer control outcomes that account for the effect of other-cause mortality (OCM). Cancer control rates are virtually equivalent between partial (PN) and radical nephrectomy (RN) for patients with T1aN0M0 renal cell carcinoma (RCC). To date, only 6 studies from centers of excellence examined cancer control rates after PN vs RN for T1aN0M0 RCC. OCM was unaccounted for in those studies, which may introduce a bias. We relied on the surveillance, epidemiology, and end results (SEER) database and assessed cancer-specific mortality (CSM) after either PN or RN for T1aN0M0 RCC, in competing-risks models.
Between 1988 and 2004, the SEER-9 database identified 1622 PN (22.3%) and 5658 RN (77.7%) T1aN0M0 RCC. Competing-risks regression models, controlling for OCM and matched for age, year of surgery, tumor size, and Fuhrman grade, addressed the effect of nephrectomy type (PN vs RN) on CSM.
At 5 years, in a PN and RN matched-population controlling for OCM, CSM after PN and RN was respectively 1.8% vs 2.5% (P = .5). The CSM rates in this cohort for patients aged ≥ 70 years were respectively 1.0% and 3.4% (P = .7).
This competing-risks population-based analysis confirmed the CSM equivalence between PN and RN for T1aN0M0 RCC and showed virtually perfect CSM-free rates (97.5% or better) even in older patients.
补充基于人群的癌症控制结果数据,这些数据考虑了其他原因死亡率(OCM)的影响。对于 T1aN0M0 肾细胞癌(RCC)患者,部分肾切除术(PN)和根治性肾切除术(RN)的癌症控制率几乎相当。迄今为止,只有 6 项来自卓越中心的研究检查了 T1aN0M0 RCC 患者接受 PN 与 RN 后的癌症控制率。这些研究没有考虑 OCM,这可能会引入偏差。我们依赖监测、流行病学和最终结果(SEER)数据库,并在竞争风险模型中评估了 T1aN0M0 RCC 接受 PN 或 RN 后癌症特异性死亡率(CSM)。
在 1988 年至 2004 年期间,SEER-9 数据库确定了 1622 例 PN(22.3%)和 5658 例 RN(77.7%)T1aN0M0 RCC。竞争风险回归模型控制了 OCM,并按年龄、手术年份、肿瘤大小和 Fuhrman 分级进行匹配,以解决肾切除术类型(PN 与 RN)对 CSM 的影响。
在 5 年时,在控制了 OCM 的 PN 和 RN 匹配人群中,PN 和 RN 后的 CSM 分别为 1.8%和 2.5%(P=0.5)。在这个队列中,年龄≥70 岁的患者的 CSM 率分别为 1.0%和 3.4%(P=0.7)。
这项基于人群的竞争风险分析证实了 T1aN0M0 RCC 患者 PN 和 RN 的 CSM 等效性,并显示了即使在老年患者中,实际上也有非常高的 CSM 无率(97.5%或更高)。